誉衡药业（002437）8月1日主力资金净流入1.97亿元

Core Insights - Harbin Yuheng Pharmaceutical Co., Ltd. (誉衡药业) reported a stock price of 4.04 yuan as of August 1, 2025, reflecting an increase of 8.89% with a turnover rate of 22.96% and a trading volume of 4.8238 million hands, amounting to 1.913 billion yuan in transaction value [1] Financial Performance - For Q1 2025, the company recorded total revenue of 551 million yuan, a year-on-year decrease of 7.06%, while net profit attributable to shareholders was 60.2523 million yuan, showing a year-on-year increase of 15.24%. The non-recurring net profit was 49.733 million yuan, up 54.74% year-on-year [1] - The company's liquidity ratios include a current ratio of 1.061, a quick ratio of 0.853, and a debt-to-asset ratio of 31.97% [1] Investment and Intellectual Property - Harbin Yuheng Pharmaceutical has made investments in 19 companies and participated in 423 bidding projects. The company holds 701 trademark registrations and 28 patents, along with 9 administrative licenses [2]